Abstracts tagged "Churg-Strauss syndrome"

Abstract Number: 1884 • 2017 ACR/ARHP Annual Meeting
Mepolizumab for the Treatment of Patients with Eosinophilic Granulomatosis with Polyangiitis: Post-Hoc Results of a Phase III Randomized, Placebo-Controlled Trial
Jonathan Steinfeld¹, Eric S Bradford², Judith Brown³, Stephen Mallett⁴, Steven W Yancey² and Michael E Wechsler⁵, ¹Respiratory TAU & Flexible Discovery Unit, GSK, Philadelphia, PA, USA, Philadelphia, PA, ²Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, USA, Research Triangle Park, NC, ³Research and Development, Immuno-Inflammation TAU, GSK, Stockley Park West, Uxbridge, Middlesex, UK, Uxbridge, United Kingdom, ⁴Research & Development, Statistics, GSK, Stockley Park West, Uxbridge, Middlesex, UK, Uxbridge, United Kingdom, ⁵Department of Medicine,, National Jewish Health, Denver, CO
Background/Purpose: In a recent Phase III study (NCT02020889) in patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA) the anti-interleukin-5 monoclonal antibody mepolizumab showed significant benefit when…
Abstract Number: 1929 • 2016 ACR/ARHP Annual Meeting
Comparison of Two Different ANCA Iif Methods with EIA and Disease Phenotype
Pooja Bhadbhade¹, Mehrdad Maz², Lowell Tilzer³, Fred Plapp³ and Jason Springer¹, ¹Allergy, Clinical Immunology and Rheumatology, The University of Kansas Medical Center, Department of Internal Medicine, Division of Allergy, Clinical Immunology and Rheumatology, Kansas City, KS, ²Allergy, Clinical Immunology, and Rheumatology, The University of Kansas Medical Center, Department of Internal Medicine, Division of Allergy, Clinical Immunology and Rheumatology, Kansas City, KS, ³Pathology and Laboratory Medicine, The University of Kansas Medical Center, Department of Pathology and Laboratory Medicine, Kansas City, KS
Background/Purpose: ANCAs are used as diagnostic markers in patients with autoimmune vasculitis such as Granulomatosis with polyangitis (GPA), Microscopic polyangitis (MPA), and Eosinophilic granulomatosis with…
Abstract Number: 1937 • 2016 ACR/ARHP Annual Meeting
Analysis of Innate and Adaptive Immune Responses in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)
Jeremie Dion^1,2, Jonathan London^2,3, Benjamin Chaigne^2,4, Nicolas Dumoitier², Bertrand Dunogué⁵, Pascal Cohen³, Matthieu Groh⁴, Claire Le Jeunne⁴, Luc Mouthon^2,5 and Benjamin Terrier^2,5, ¹Internal medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²INSERM U1016, Institut Cochin, Equipe Neutrophiles et Vascularites, Paris, France, ³Internal Medecine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁴National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁵Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA, formerly called Churg-Strauss syndrome) belongs to ANCA-associated vasculitis and is characterized by late onset asthma, blood and tissue eosinophilia…
Abstract Number: 1940 • 2016 ACR/ARHP Annual Meeting
High Prevalence of Inflammatory Heart Disease in Eosinophillic Granulomatosis with Polyangiitis (Churg Strauss) Patients
Eloi Garcia Vives¹, Len Harty² and David Jayne³, ¹Vall d'Hebrón Hospital, Barcelona, Spain, ²Vasculitis & Lupus, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ³Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom
Background/Purpose: To establish EGPA/Churg Strauss inflammatory heart disease prevalence and develop an algorithm for heart disease screening in EGPA patients. Methods: An audit of all…
Abstract Number: 870 • 2015 ACR/ARHP Annual Meeting
Development of an Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Patient-Reported Outcome Measure: Identification of Salient Themes and Candidate Questionnaire Item Development
Joanna Robson¹, Susan Ashdown², Jill Dawson³, Ebony Easley⁴, Don Gebhart⁵, Katherine Kellom⁶, Georgia Lanier⁷, Carol McAlear⁸, Nataliya Milman⁹, Jacqueline Peck¹⁰, Judy A. Shea¹¹, Gunnar Tomasson¹², Raashid Luqmani¹³, Peter F. Cronholm⁴ and Peter A. Merkel⁸, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, University of Oxford, Oxford, United Kingdom, ²NONE, Banbury, United Kingdom, ³Nuffield Department of Population Health HSRU, University of Oxford, Oxford, United Kingdom, ⁴Department of Family Medicine and Community Health, The University of Pennsylvania, Philadelphia, PA, ⁵NONE, Columbus, OH, ⁶PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, United Kingdom, ⁷NONE, Framingham, MA, ⁸Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁹Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ¹⁰NONE, Oxford, United Kingdom, ¹¹Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, United Kingdom, ¹²Rheumatology Section, Boston University, Boston, MA, ¹³Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: Patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs), including granulomatosis with polyangiitis (Wegener's, (GPA), eosinophilic granulomatosis with polyangiitis (Churg-Strauss, EGPA), and microscopic polyangiitis (MPA),…
Abstract Number: 889 • 2015 ACR/ARHP Annual Meeting
Central Nervous System Involvement of Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss): Retrospective Analysis of 26 Cases and Review of the Literature
Raphael André¹, Chahéra Khouatra², Jean-Luc Saraux³, Francois Maurier⁴, Gilles Blaison⁵, Boris Bienvenu⁶, Pascal Cathebras⁷, Nathalie Costedoat-Chalumeau⁸, Robin Dhote⁹, Aurélie Foucher¹⁰, Helder Gil¹¹, Joelle Lapouarie¹², David Launay¹³, Edouard Pertuiset¹⁴, Valentine Loustau¹⁵, Thierry Zenone¹⁶, Claire Le Jeunne¹⁷, Luc Mouthon¹⁸, Loïc Guillevin¹⁹ and Benjamin Terrier²⁰, ¹Cochin Hospital, Paris, France, ²CHU Lyon, Lyon, France, ³CH Eaubonne, Eaubonne, France, ⁴HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ⁵Internal medicine, CHR, Colmar, France, ⁶Internal Medicine, Hospital Caen, Caen, France, ⁷Internal Medicine, University Hospital St Etienne, St Etienne, France, ⁸Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ⁹Internal Medicine, Hospital Avicenne, Bobigny, France, ¹⁰CHU, Saint Pierre de la Réunion, France, ¹¹CHU, Besancon, France, ¹²CHU, Pau, France, ¹³Service de Médecine Interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, ¹⁴CH René Dubos, Pontoise, France, ¹⁵Hôpital Henri Mondor, Créteil, France, ¹⁶CH de Valence, Valence, France, ¹⁷Department of Internal Medicine, Hotel-Dieu Hospital, AP-HP, Paris, Paris, France, ¹⁸Department of Internal Medicine, Department of Internal Medicine, Cochin Hospital, Referent Center for Necrotizing Vasculitis and Systemic Sclerosis, Paris-Descartes University, AP-HP, Paris, France, ¹⁹Internal Medicine, Hopital Cochin, Paris, France, ²⁰Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is characterized by asthma, blood and tissue eosinophilia, vasculitis-related peripheral neuropathy, glomerulonephritis or skin symptoms. Although peripheral nervous system…
Abstract Number: 890 • 2015 ACR/ARHP Annual Meeting
Anti-IgE Monoclonal Antibody in Refractory and/or Relapsing Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss): Data from 17 Patients
Marie Jachiet¹, Maxime Samson², Vincent Cottin³, Jean-Emmanuel Kahn⁴, Guillaume Le Guenno⁵, Philippe Bonniaud⁶, Laurence Bouillet⁷, Anne Gondouin⁸, Fatma Makhlouf⁷, Nadine Meaux Ruault⁹, Helder Gil⁸, Hervé Devilliers¹⁰, Boris Bienvenu¹¹, André Coste¹², Violaine Giraud¹³, Stephane Dominique¹⁴, Bertrand Godeau¹⁵, Xavier Puéchal¹⁶, Chahéra Khouatra¹⁷, Marc Ruivard¹⁸, Claire Le Jeunne¹⁹, Luc Mouthon²⁰, Loïc Guillevin²¹ and Benjamin Terrier¹⁶, ¹Dermatology, Cochin Hospital, Paris, France, ²Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ³Division of Pneumology, Hôpital Louis-Pradel, Hospices Civils de Lyon, Lyon 1, Lyon, France, ⁴Internal Medicine, Foch Hospital, Suresnes, France, ⁵Internal Medicine department, Clermont-Ferrand, France, ⁶CHU, Dijon, France, ⁷CHU, Grenoble, France, ⁸CHU, Besancon, France, ⁹Internal Medicine and Clinical Immunology, CHU de Besançon, Besançon, France, ¹⁰Department of Internal Medicine and Systemic Diseases, Dijon University Hospital, Dijon, France, ¹¹Internal Medicine, Hospital Caen, Caen, France, ¹²CHI, Créteil, France, ¹³Hôpital Ambroise Paré, Boulogne Billancourt, France, ¹⁴Pneumology, Rouen University Hospital, Rouen, France, ¹⁵Henri Mondor, Créteil, France, ¹⁶Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ¹⁷CHU Lyon, Lyon, France, ¹⁸CHU Clermont-Ferrand, Clermont–Ferrand, France, ¹⁹Department of Internal Medicine, Hotel-Dieu Hospital, AP-HP, Paris, Paris, France, ²⁰Department of Internal Medicine, Department of Internal Medicine, Cochin Hospital, Referent Center for Necrotizing Vasculitis and Systemic Sclerosis, Paris-Descartes University, AP-HP, Paris, France, ²¹Internal Medicine, Hopital Cochin, Paris, France
Background/Purpose: Omalizumab, an anti-IgE monoclonal antibody, has proven efficacy for the treatment of moderate-to-severe and severe-persistent allergic asthma and allergic rhinitis, with a favorable safety…
Abstract Number: 1786 • 2014 ACR/ARHP Annual Meeting
Vasculitis As Underlying Cause of Death in the United States: 1999 – 2010
Alicia Rodriguez-Pla¹, Paul A. Monach² and Jose Rossello-Urgell³, ¹Rheumatology, Boston University, Boston, MA, ²Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA, ³Baylor Research Institut, Baylor Institute for Immunology Research, Dallas, TX
Background/Purpose Current data on mortality rates of primary vasculitis, which were tradionally associated with a dreadful prognosis, are limited. Therefore, we aimed to estimate the mortality rates…
Abstract Number: 1763 • 2014 ACR/ARHP Annual Meeting
Tobacco Differentially Affects the Clinical-Biological Phenotype of ANCA-Associated Vasculitides at Diagnosis
Lucas Benarous¹, Benjamin Terrier², Bertrand Dunogué³, Pascal Cohen⁴, Xavier Puéchal⁴, Claire Le Jeunne⁴, Luc Mouthon⁴ and Loïc Guillevin for the French Vasculitis Study Group⁴, ¹Cochin Hospital, Paris, France, ²National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ³Internal Medicine, Hôpital Cochin, Paris, France, ⁴National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France
Background/Purpose Occupational and non-occupational exposures may play a role in the occurrence of ANCA-associated vasculitides (AAV) and affect their initial clinical-biological phenotype. Among these potential…
Abstract Number: 756 • 2013 ACR/ARHP Annual Meeting
Clinical Value Of Commonly-Measured Laboratory Tests In Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)
Peter C. Grayson¹, Paul A. Monach², David Cuthbertson³, Simon Carette⁴, Gary S. Hoffman⁵, Nader A. Khalidi⁶, C. L. Koening⁷, Carol A. Langford⁸, Kathleen Maksimowicz-McKinnon⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Ulrich Specks¹², Steven R. Ytterberg¹³ and Peter A. Merkel¹⁴, ¹NIAMS, National Institutes of Health, Bethesda, MD, ²Rheumatology, Boston University, Boston, MA, ³Department of Biostatistics, University of South Florida, Tampa, FL, ⁴Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁵Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁶Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, ⁷Internal Medicine, Salt Lake City Veterans Administration, Salt Lake City, UT, ⁸Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁹Rheumatology, Henry Ford Hospital, Detroit, MI, ¹⁰Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Canada, ¹¹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, Rochester, MN, ¹³Rheumatology Division, Mayo Clinic, Rochester, MN, ¹⁴Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Serial measurement of absolute eosinophil count (Eos), serum immunoglobulin E (IgE), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) is common practice in the…
Abstract Number: 757 • 2013 ACR/ARHP Annual Meeting
Impact Of Cardiac Magnetic Resonance Imaging On Eosinophilic Granulomatosis With Polyangiitis Outcomes: A Long-Term Retrospective Study On 42 Patients
Bertrand Dunogué¹, Pascal Cohen², Benjamin Terrier³, Julien Marmursztejn⁴, Denis Duboc⁴, Olivier Vignaux⁵ and Loic Guillevin³, ¹Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ²National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ³Internal Medicine, Cochin University Hospital, Paris, France, ⁴Cardiology, Cochin University Hospital, Paris, France, ⁵Radiology, Cochin University Hospital, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) cardiomyopathy carries a poor prognosis, and is the main cause of 1st-year and long-term mortality. Morbidity due to chronic…
Abstract Number: 758 • 2013 ACR/ARHP Annual Meeting
Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss Syndrome) – Re-Analysis Of The French Vasculitis Study Group Cohort Using Different Disease Definitions and Cluster Analysis
Christian Pagnoux¹, Pascal N. Tyrrell², Chiara Baldini³, Simon Carette¹, Jean-Francois Cordier⁴, Loic Guillevin⁵ and French Vasculitis Study Group FVSG⁶, ¹Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ²Department of Medical Imaging, University of Toronto, Toronto, ON, Canada, ³University of Pisa, Rheumatology Unit, Pisa, Italy, ⁴Division of Pneumology, Hôpital Louis-Pradel, Hospices Civils de Lyon, Lyon 1, Lyon, France, ⁵Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ⁶Internal Medicine, Service de médecine interne, Centre de Références des Vascularites, Université Paris Descartes, APHP, Hôpital Cochin, 75005 Paris, France., Paris, France
Background/Purpose: Because only 25–40% of the patients are ANCA+ and biopsy is not always taken or helpful, EGPA diagnosis can be challenging. Previous cohort analyses…
Abstract Number: 759 • 2013 ACR/ARHP Annual Meeting
Eosinophilic Granulomatosis With Polyangiitis (Churg–Strauss Syndrome): Comparison Of The Independent French Vasculitis Study Group and Italian–Pisa Patient Cohorts and Cross-Validation Of Cluster Analysis
Chiara Baldini¹, Pascal N. Tyrrell², Manuela Latorre³, Simon Carette⁴, Nader A. Khalidi⁵, Veronica Seccia⁶, Loic Guillevin⁷ and Christian Pagnoux⁴, ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²Department of Medical Imaging, University of Toronto, Toronto, ON, Canada, ³University of Pisa, Pneumology Unit, Pisa, Italy, ⁴Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁵Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, ⁶Unit of Otorhinolaryngology, Department of Neuroscience, University of Pisa, Pisa, Italy, Pisa, Italy, ⁷Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: Previous analyses of the FVSG- and Pisa-cohort EGPA patients identified several covariates associated with poor outcomes and suggested differences between ANCA+ and ANCA– EGPA-patient…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].